Nature Communications · 2018 · 404 citations · 38 references
MedicineOncologyPharmacologyCancer ImmunologyChemotherapyImmunotherapyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmunotherapy SafetyTumor Microenvironment ModulationImmune Checkpoint Blockade CombinationsImmune Checkpoint Blockade SynergyImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor TherapyOxaliplatin-based TherapyPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayTumor Microenvironment Effects
Although great success has been obtained in the clinic, the current immune checkpoint inhibitors still face two challenging problems: low response rate and immune-related adverse effects (irAEs). Here we report the combination of immunogenic chemotherapy and locally expressed PD-L1 trap fusion protein for efficacious and safe cancer immunotherapy. We demonstrate that oxaliplatin (OxP) boosts anti-PD-L1 mAb therapy against murine colorectal cancer. By design of a PD-L1 trap and loading its coding plasmid DNA into a lipid-protamine-DNA nanoparticle, PD-L1 trap is produced transiently and locally in the tumor microenvironment, and synergizes with OxP for tumor inhibition. Significantly, unlike the combination of OxP and anti-PD-L1 mAb, the combination of OxP and PD-L1 trap does not induce obvious Th17 cells accumulation in the spleen, indicating better tolerance and lower tendency to irAEs. The reports here may highlight the potential of applying PD-L1 inhibitor, especially locally expressed PD-L1 trap, in cancer therapy following OxP-based chemotherapy.
38
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.7K citations
Medicine, Oncology, Pharmacotherapy +16
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng, Hua Liang, Byron Burnette et al. · Journal of Clinical Investigation · 2014 · 2.1K citations
Medicine, Immunology, Oncology +17
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Mahesh Yadav, Suchit Jhunjhunwala, Qui Phung et al. · Nature · 2014 · 1.2K citations
Medicine, Immunology, Oncology +16